PMID- 17004936
OWN - NLM
STAT- MEDLINE
DCOM- 20070105
LR  - 20181211
IS  - 0953-816X (Print)
IS  - 0953-816X (Linking)
VI  - 24
IP  - 6
DP  - 2006 Sep
TI  - Neurokinin receptor antagonism attenuates cocaine's behavioural activating 
      effects yet potentiates its dopamine-enhancing action in the nucleus accumbens 
      core.
PG  - 1721-32
AB  - Several lines of evidence indicate a role for neurokinin3 receptors (NK3-Rs) in 
      behavioural activation and mechanisms governing reinforcement processes. In this 
      study we investigated the effect of pretreatment with the NK3-R antagonist, 
      SR142801, (0.2 and 2.0 mg/kg) on the cocaine-induced (10.0 mg/kg i.p.) increase 
      in extracellular dopaminergic activity in the nucleus accumbens (NAc). In vivo 
      microdialysis in the NAc of freely moving rats showed that cocaine increased 
      concentrations of dopamine (DA) to approximately 350% in the core and 
      approximately 450% in the shell. Pre-treatment with SR142801 significantly 
      potentiated this effect in the core (to approximately 550%), whereas this effect 
      was not found in the shell. We also investigated the effects of NK3-Rs antagonism 
      on cocaine-induced hyperactivity and conditioned place preference. SR142801 
      blocked the hyperactivity, but neither the conditioned place preference nor the 
      conditioned locomotor activity induced by cocaine, although there was a slight 
      tendency towards a reduced place preference. When given alone, SR142801 had no 
      effects on behaviour or extracellular dopamine concentrations in any of the 
      structures investigated. These data provide evidence for a contribution of NK3-Rs 
      in the acute behavioural and neurochemical effects of cocaine, involving 
      dopaminergic activity in the core of the nucleus accumbens.
FAU - Jocham, Gerhard
AU  - Jocham G
AD  - Institute of Physiological Psychology and Center for Biological and Medical 
      Research, University of Dusseldorf, Universitatsstr.1, D-40225, Dusseldorf, 
      Germany. desouza@uni-duesseldorf.de
FAU - Lezoch, Katharina
AU  - Lezoch K
FAU - Muller, Christian P
AU  - Muller CP
FAU - Kart-Teke, Emriye
AU  - Kart-Teke E
FAU - Huston, Joseph P
AU  - Huston JP
FAU - de Souza Silva, M Angelica
AU  - de Souza Silva MA
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - France
TA  - Eur J Neurosci
JT  - The European journal of neuroscience
JID - 8918110
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Dopamine Uptake Inhibitors)
RN  - 0 (Piperidines)
RN  - 0 (Receptors, Neurokinin-3)
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - I5Y540LHVR (Cocaine)
RN  - K7G81N94DT (SR 142801)
RN  - VTD58H1Z2X (Dopamine)
RN  - X77S6GMS36 (Homovanillic Acid)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/metabolism
MH  - Analysis of Variance
MH  - Animals
MH  - Antipsychotic Agents/pharmacology
MH  - Behavior, Animal/*drug effects/physiology
MH  - Cocaine/*pharmacology
MH  - Conditioning, Operant/drug effects/physiology
MH  - Dopamine/*metabolism
MH  - Dopamine Uptake Inhibitors/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Interactions
MH  - Extracellular Fluid/drug effects
MH  - Homovanillic Acid/metabolism
MH  - Locomotion/drug effects
MH  - Male
MH  - Microdialysis/methods
MH  - Nucleus Accumbens/*drug effects
MH  - Piperidines/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Receptors, Neurokinin-3/*antagonists & inhibitors
EDAT- 2006/09/29 09:00
MHDA- 2007/01/06 09:00
CRDT- 2006/09/29 09:00
PHST- 2006/09/29 09:00 [pubmed]
PHST- 2007/01/06 09:00 [medline]
PHST- 2006/09/29 09:00 [entrez]
AID - EJN5041 [pii]
AID - 10.1111/j.1460-9568.2006.05041.x [doi]
PST - ppublish
SO  - Eur J Neurosci. 2006 Sep;24(6):1721-32. doi: 10.1111/j.1460-9568.2006.05041.x.